AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$TELA

Capper Joseph H purchased $89K of TELA

Capper Joseph H purchased 75,000 shares of TELA Bio, Inc. (TELA) at an average of $1.18 ($1.17–$1.22) across 2 trades over 2026-09-16 to 2026-09-17.

Original reporting
SEC EDGAR · Capper Joseph H
Published Sep 18, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TELA
Neutral
high confidence
Mentioned
$TELA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TELANeutralLow
01

Why it matters

Director buy adds modest shares; unlikely to affect market perception significantly.

02

Market read

Minor insider purchase; limited trading relevance.

03

What to watch

Potential upcoming clinical data could make the insider buy more significant in hindsight.

Relevance 4/10Novelty 4/10Timing: filed Sep 18 2026

Background

Form 4 filing discloses insider transactions; this is the first public report of the purchase.

Company-level read

Ticker impact

$TELANeutralHigh confidence
Context

Director Capper Joseph H purchased 75,000 shares for $88,795, increasing his stake to 179,827 shares.

Expected impact

minimal impact, possible slight positive bias

Evidence & confidence

Purchase size is modest relative to market cap; director ownership already sizable.

Market effects

Sector

None; biotech sector not affected by a single director purchase.

Regional

None

Global

None

Counterpoint

What could challenge this read

The purchase may signal confidence, but size is too small to be meaningful.

Key entities

  • Director
    Capper Joseph H

    Insider who purchased shares.

  • Company
    TELA Bio, Inc.

    Biotech firm listed on Nasdaq under ticker TELA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TELA insider trading history →

Related articles

OCT 5
$TELAMedAI 8/10

TELA Bio Announces 510(k) Clearance for LioraTM Monofilament Scaffold for Soft Tissue Reinforcement

TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 TELA Bio Announces 510(k) Clearance for Liora TM Monofilament Scaffold for Soft Tissue Reinforcement MALVERN, PA, October 5, 2026 -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissu

SEC EDGAR 8-K2 min
AUG 19
$TELAMed

TELA Bio (TELA) Q2 2026 Earnings Call Transcript

TELA Bio reported Q2 2026 revenue of $19.3M, down 4% YoY, driven by declines in OviTex PRS unit volumes and price-mix headwinds. International revenue grew 26% YoY, while gross margin improved to 72%. Net loss was $11.3M, and cash reserves decreased to $30.4M. Management cited competitive pressures and slower sales rep productivity as challenges, while highlighting market share gains in hernia products and plans to reduce costs.

fool.com3 min
AUG 10
$TELAMed

TELA Bio Reports Second Quarter 2026 Financial Results

TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TELA Bio Reports Second Quarter 2026 Financial Results MALVERN, PA, August 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results fo

SEC EDGAR 8-K4 min